From: BMG <bmg.bund.de>
Sent: 09 June 2020 21:01
To: GAUER Celine (SG-RECOVER)
Cc: (SG);
(BUDG);
@minvws.nl

Subject: AW: Draft Term Sheet for Commercial Supply of ChAdOx1 nCoV-19 vaccine (AZD 1222)
in Europe (ex-UK).

Sensitivity: Confidential
Follow Up Flag: Follow up
Flag Status: Completed

Categories: TO REGISTER

Chère Céline,

Thank you for this fast check and reply. That is good news.

Concerning AZ, the partners have decided to continue to negotiate with AZ on some remaining crucial points until tomorrow evening. Tomorrow evening will be another high level meeting to hopefully conclude the negotiations and consent on AZ and decide together next steps including COM. Your informations will be an important basis, helpful would be also if you could transmit a draft of the agreement mentioned under no 2.

?Cordialy, 


Bundesministerium für Gesundheit
@bmg.bund.de

Von: Celine.Gauer@ec.europa.eu
An: BMG
Cc: @ec.europa.eu; @ec.europa.eu; @it; @pm.gouv.fr; @minvws.nl

Betreff: RE: Draft Term Sheet for Commercial Supply of ChAdOx1 nCoV-19 vaccine (AZD 1222) in Europe (ex-UK).

Dear ,


Thanks for sharing the term sheet with us. It is a very interesting offer which is likely to be of interest for many Member States.

As agreed, we have checked whether the Commission could sign it on behalf of the Member States. I can confirm that this is the case and that we would be ready to do so from Friday onwards.

I can also confirm that I understand that this is implicit in the term sheet.

This would only require that:

1. the text of the term sheet is adjusted to reflect that the Commission would be a signatory and The Member States would take.

2. An agreement is signed by the Commission with the participating Member States on behalf of whom the Commission would be purchasing (requirement under Article 4(5)b). A draft of such agreement is being prepared along the lines of the paper presented by the Commission to the Council this week and could be shared with the Member States after COREPER tomorrow.

On substance, I think that the following points would warrant another discussion between all of us and with Astra Zeneca:

1. ,
2. ,
3. ,
4. ,
5.
6.
We are ready to engage immediately in such discussion together with you and the other members of the alliance.

Finally, on communication, given the leadership taken by the alliance, I think that it would be important to communicate jointly on the signature of the term-sheet and use this example to show how Member States and the Commission united together can act swiftly to fight the pandemic and protect the citizens.

I suggest that we have another call asap.
Kind regards
Céline